

## References

### I-233

1. Liebow A, Li X, Racie T, et al. An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria. *J Am Soc Nephrol.* 2017;28:494-503.
2. Oxulumo (lumasiran), injection, for subcutaneous use [package insert]. Alnylam Pharmaceuticals, Inc. Cambridge, MA. Revised 10/2022.
3. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Lumisiran.
4. Micromedex DrugDex Compendium®. 2022. Lumisiran.
5. Lumisiran In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated December 14, 2020.
6. Frishberg Y, Deschenes G, Groothoff JW, et al. Phase ½ study of lumasiran for treatment of primary hyperoxaluria type 1: A placebo-controlled randomized clinical trial. 2021;16:1025-36.
7. Hulton SA, Groothoff JW, Frishberg Y, et al. Randomized clinical trial on the long-term efficacy and safety of lumasiran in patients with primary hyperoxaluria type 1. *Kidney Int Rep.* 2022;7:494-506.
8. Garrelfs SF, Frishberg Y, Hulton SA, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. *NEJM.* 2021;384:1216-26.
9. Sas DJ, Magen D, Hayes W, et al. Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children. *Genetics in Medicine.* 2022;24:654-62.
10. Michael M, Groothoff JW, Shasha-Lavsky H, et al. Lumasiran for advanced primary hyperoxaluria type 1: Phase 3 ILLUMINATE-C trial. *AJKD.* 2022;S0272-6386(22):00771-5.